Nasdaq · Healthcare
RIGEL PHARMACEUTICALS INC (RIGL)
As-reported financials and recent SEC filings for RIGEL PHARMACEUTICALS INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$294.3M
Net income
$367.0M
Net margin
124.7%
Diluted EPS
$19.48
ROE
93.8%
P/E (TTM)
2.0×
Market cap
$715.8M
Debt / equity
0.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $294.3M | $179.3M | $116.9M | $120.2M | $149.2M |
| Gross profit | — | $160.6M | — | — | — |
| Operating income | $125.5M | $24.2M | $-20.5M | $-55.5M | $-12.5M |
| Net income | $367.0M | $17.5M | $-25.1M | $-58.6M | $-17.9M |
| Diluted EPS | $19.48 | $0.99 | $-1.44 | $-3.44 | $-1.10 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-24
View on EDGAR →1442026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →8-K2026-06-17
View on EDGAR →Go deeper on RIGL
Search RIGEL PHARMACEUTICALS INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.